Avicanna (TSX:AVCN) Investments And Advances : C$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Avicanna Investments And Advances?

Avicanna's Investments And Advances for the quarter that ended in Dec. 2023 was C$0.00 Mil.

Avicanna's annual Investments And Advances declined from Dec. 2021 (C$0.18 Mil) to Dec. 2022 (C$0.00 Mil) but then stayed the same from Dec. 2022 (C$0.00 Mil) to Dec. 2023 (C$0.00 Mil).

Avicanna Investments And Advances Historical Data

The historical data trend for Avicanna's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avicanna Investments And Advances Chart

Avicanna Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

0.52

0.18

Avicanna Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Investments And Advances	Get a 7-Day Free Trial															-	-	-	-	-

Avicanna Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Avicanna (TSX:AVCN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avicanna Inc (TSX:AVCN) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

AVCNF:USA 0NN:Germany

Address

480 University Avenue, Suite 1502, Toronto, BC, CAN, M5G 1V2

Website

https://www.avicanna.com

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

Executives

Sheldon Inwentash

10% Security Holder

Avicanna (TSX:AVCN) Headlines

No Headlines